Funder
National Key Research and Development Plan of China
National Natural Science Foundation of China
Strategic Priority Research Program from Chinese Academy of Sciences
International Innovation Team of CAS
Beijing Municipal Science and Technology Commission
Institute of Automation, Chinese Academy of Sciences
Reference41 articles.
1. Nalley and Catlin, Regorafenib Granted Priority Review for Treatment of Liver Cncer.
2. Disability-adjusted Life Years (DALYs) for 291 Diseases and Injuries in 21 Regions;Murray,2017
3. Hepatocellular carcinoma surveillance: the road ahead;Hernaez;Hepatology,2017
4. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States;Ju;Cancer,2017
5. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies;Olsen;Ther. Adv. Gastroenterol.,2010
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献